Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

BACKGROUND: CC-486 is an oral formulation of the epigenetic modifier azacitidine. In an expanded phase 1 trial, CC-486 demonstrated clinical and biological activity in patients with International Prognostic Scoring System (IPSS) lower-risk (low- and intermediate-1–risk) myelodysplastic syndromes (MD...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Manero, Guillermo, Almeida, Antonio, Giagounidis, Aristoteles, Platzbecker, Uwe, Garcia, Regina, Voso, Maria Teresa, Larsen, Stephen R., Valcarcel, David, Silverman, Lewis R., Skikne, Barry, Santini, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855808/
https://www.ncbi.nlm.nih.gov/pubmed/27148452
http://dx.doi.org/10.1186/s12878-016-0049-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855808/
https://www.ncbi.nlm.nih.gov/pubmed/27148452
http://dx.doi.org/10.1186/s12878-016-0049-5

Ejemplares similares